



Vivimed

Date: 12/11/2016

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

BSE - Code : 532660

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.

The Board of Directors of the Company at its meeting held on November 12, 2016 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter & half year ended September 30, 2016 attached herewith;
2. Auditors's Limited Review Report on the Un -audited Financial Statements of the Company for the for the Quarter & half year ended September 30, 2016.

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

For Vivimed Labs Limited


SANTOSH VARALWAR
MANAGING DIRECTOR



Vivimed Labs Ltd. (Corporate Office)

CIN : L02411KA1988PLC009465

Veernag Towers, Habsiguda, Hyderabad, Telangana - 500 007, India

T +91 (0) 40-2717 6005/6 F +91 (0) 40-2715 0599

contact@vivimedlabs.com www.vivimedlabs.com

VIVIMED LABS LIMITED
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEP'2016

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Previous Year ended 31.03.2016	Rs. in Lacs
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015		
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	(a) Net Sales / Income from Operations (Net of Excise Duty)	29,836.48	36,683.04	33,702.81	66,519.52	66,855.65	1,34,562.99	
	(b) Other Operating Income	92.09	176.60	452.10	268.69	595.70	1,080.98	
	Total Income From Operations (Net)	29,928.57	36,859.64	34,154.91	66,788.21	67,451.35	1,35,643.97	
	a. Cost of Raw Materials Consumed	14,290.03	16,775.35	15,448.89	31,065.38	30,821.59	60,969.16	
	b. Purchase of Stock in Trade							
	c. Changes in Inventories of finished Inventories Goods, Work-in-Progress and Stock in Trade	(862.15)	418.24	497.50	(443.91)	(56.42)	1,435.62	
	d. Employee Benefit Expenses	4,141.09	5,014.77	3,776.21	9,155.86	8,319.24	17,694.25	
	e. Depreciation and Amortisation Expenses	1,493.79	1,584.40	1,638.86	3,078.19	3,117.24	6,139.34	
	f. Other Expenditure	6,237.42	7,966.50	8,114.71	14,203.92	15,327.13	31,255.74	
2	Total Expenses	25,300.18	31,759.26	29,476.17	57,059.44	57,528.78	1,17,494.11	
3	Profit / (Loss) from Operations before Other Income Finance Costs and exceptional Items (1 - 2)	4,628.39	5,100.38	4,678.74	9,728.77	9,922.57	18,149.86	
4	Other Income							
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional Items (3 - 4)	4,628.39	5,100.38	4,678.74	9,728.77	9,922.57	18,149.86	
6	Finance Costs	1,494.21	1,520.84	1,879.61	3,015.05	3,784.12	8,156.63	
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional Items (5 - 6)	3,134.18	3,579.54	2,799.13	6,713.72	6,138.45	9,993.24	
8	Exceptional Items							
9	Profit / Loss from ordinary activities before Tax (7 - 8)	3,134.18	3,579.54	2,799.13	6,713.72	6,138.45	9,993.24	
10	Tax Expenses	448.96	793.61	411.53	1,242.57	1,333.51	1,625.93	
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	2,685.23	2,785.93	2,387.60	5,471.16	4,804.94	8,367.32	
12	Extraordinary Items (net of tax expenses Rs.Lacs)							
13	Net Profit / Loss for period (11 - 12)	2,685.23	2,785.93	2,387.60	5,471.16	4,804.94	8,367.32	
14	Share of Profit / (Loss) of associates							
15	Minority Interest							
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	2,685.23	2,785.93	2,387.60	5,471.16	4,804.94	8,367.32	
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year							
19	Earnings per Share (before Extraordinary Items) (of Rs.2/- each) (not annualised)							
	(a) Basic	3.31	3.44	2.95	6.75	5.93	10.33	
	(b) Diluted	3.22	3.34	2.86	6.55	5.75	10.02	

- The above Consolidated Unaudited Financial Results for the Quarter & Half year ended SEPTEMBER 30TH 2016 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 12th NOVEMBER 2016
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Kar Sehen Private Limited, (iv) Octants Nobel Labs Private Limited, (v) Vivimed Labs (Aachen) Pvt. Limited (vi) Finoso Pharma Pvt Limited (vii) Vivimed specialty chemicals Pvt Ltd viz (viii) Vivimed Holdings Limited and its stepdown subsidiary Vivimed Labs Europe Limited (ix) Vivimed Labs Mauritius Limited and its stepdown subsidiaries (i) Vivimed Labs UK Limited, (ii) Vivimed Labs Spain, S.L. (iii) Union Quimico Farmaceutica S.A.U., Spain, (iv) Holiday International Limited, UK & (v) Uqulja Mexico S.A. de C.V.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
 Date : 12.11.2016

For VIVIMED LABS LIMITED

 (SANKAR VARALWAR)
 MANAGING DIRECTOR



VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED

Rs. in Lacs

Particulars	3 Months Ended			Half Year Ended		FY 15 31-03-2016 (Audited)
	30.09.2016 (Unaudited)	30.06.2016 (Unaudited)	30.09.2015 (Unaudited)	30.09.2016 (Unaudited)	30.09.2015 (Unaudited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)						
a. Speciality Chemicals Business	8,106.78	7,998.67	9,430.16	16,105.45	19,005.58	37,141.35
b. Pharma Business	21,729.71	28,684.37	24,272.64	50,414.08	47,850.07	97,421.63
Total	29,836.48	36,683.04	33,702.80	66,519.52	66,855.65	1,34,562.98
Less: Inter Segment Revenue						
Net sales / Income from Operations	29,836.48	36,683.04	33,702.80	66,519.52	66,855.65	1,34,562.98
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment						
a. Speciality Chemicals Business	2,070.50	1,519.15	2,111.07	3,589.65	3,851.46	6,796.84
b. Pharma Business	2,557.89	3,581.23	2,567.67	6,139.12	6,071.10	11,353.02
Total	4,628.39	5,100.38	4,678.74	9,728.77	9,922.56	18,149.86
Less: 1. Interest	1,494.21	1,520.84	1,879.61	3,015.05	3,784.12	8,156.63
2. Other Un-allocable Expenditure						
3. Un-allocable Income						
Total Profit Before Tax	3,134.18	3,579.54	2,799.13	6,713.72	6,138.44	9,993.23
3. Capital Employed						
a. Speciality Chemicals Business	71,716.20	78,275.46	74,152.66	71,716.20	74,152.66	84,539.58
b. Pharma Business	87,253.78	79,728.15	66,437.84	87,253.78	66,437.84	70,862.31
Total	1,58,969.98	1,58,003.61	1,40,590.50	1,58,969.98	1,40,590.50	1,55,401.89

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR



Place : Hyderabad
Date : 12.11.2016

VIVIMED LABS LIMITED
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEP 2016

Rs. in Lacs

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Previous Year ended 31.03.2016 (Audited)
		30.09.2016 (Unaudited)	30.06.2016 (Unaudited)	30.09.2015 (Unaudited)	30.09.2016 (Unaudited)	30.09.2015 (Unaudited)	
1	Income From Operations						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	6,771.22	7,236.27	8,009.12	14,007.49	15,980.44	31,939.36
	(b) Other Operating Income	0.34	0.70	17.48	1.04	30.18	98.38
	Total Income from Operations (Net)	6,771.56	7,236.96	8,026.61	14,008.53	16,010.62	32,037.74
	a. Cost of Raw Materials Consumed	2,746.31	4,096.01	2,861.20	6,842.32	6,316.40	12,467.66
	b. Purchase of Stock in Trade						
	c. Changes in Inventories of finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	236.63	(968.29)	394.47	(731.67)	381.58	686.79
	d. Employee Benefit Expenses	557.60	622.59	604.85	1,180.20	1,134.62	2,399.35
	e. Depreciation and Amortisation Expenses	441.25	516.49	412.75	957.73	897.26	1,879.24
	f. Other Expenditure	1,421.33	1,564.58	1,973.72	2,985.91	3,726.66	7,864.80
2	Total Expenses	5,403.12	5,831.37	6,246.99	11,234.49	12,456.53	25,297.84
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	1,368.44	1,405.59	1,779.62	2,774.04	3,554.09	6,739.90
4	Other Income						
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	1,368.44	1,405.59	1,779.62	2,774.04	3,554.09	6,739.90
6	Finance Costs	1,157.77	1,132.37	1,502.14	2,290.15	2,994.96	5,605.93
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	210.67	273.22	277.48	483.89	559.13	1,133.97
8	Exceptional Items						
9	Profit / Loss from ordinary activities before Tax (7 - 8)	210.67	273.22	277.48	483.89	559.13	1,133.97
10	Tax Expenses	42.13	54.64	50.43	96.78	115.29	321.16
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	168.54	218.58	227.05	387.11	443.84	812.81
12	Extraordinary Items (net of tax expenses Rs. Lacs)						
13	Net Profit / Loss for period (11 - 12)	168.54	218.58	227.05	387.11	443.84	812.81
14	Share of Profit / (Loss) of associates						
15	Minority Interest						
16	Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	168.54	218.58	227.05	387.11	443.84	812.81
17	Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38	1,620.38
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year						
19	Earnings per Share (before Extraordinary Items) (a) Rs2/- each (not annualised)	0.21	0.27	0.28	0.48	0.55	1.00
	(b) Diluted	0.20	0.26	0.27	0.46	0.53	0.97

1. The above Standalone Unaudited Financial Results for the Quarter & Half year ended SEPTEMBER 30TH 2016 have been reviewed by Audit committee and taken on record by Board of Directors at their meeting held on 12th NOVEMBER, 2016

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been regrouped, wherever necessary.

Place : Hyderabad
 Date : 12.11.2016

For VIVIMED LABS LIMITED
 (SANTOSH VARALWAR)
 MANAGING DIRECTOR



VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED

Rs. in Lacs

Particulars	3 Months Ended				Half Year Ended		FY 15	
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31-03-2016		
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
1. Segment Revenue <i>(net sales/income from each segment should be disclosed under this head)</i>								
a. Speciality Chemicals Business	4,500.61	5,430.61	5,914.68	9,931.22	11,980.72	24,113.40		
b. Pharma Business	2,270.61	1,805.66	2,094.44	4,076.27	3,999.72	7,825.96		
Total	6,771.22	7,236.27	8,009.12	14,007.49	15,980.44	31,939.36		
Less, Inter Segment Revenue								
Net sales / Income from Operations	6,771.22	7,236.27	8,009.12	14,007.49	15,980.44	31,939.36		
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment								
a. Speciality Chemicals Business	1,020.92	1,178.47	1,583.55	2,199.39	3,220.45	5,918.33		
b. Pharma Business	347.53	227.12	196.07	574.65	333.64	821.58		
Total	1,368.44	1,405.59	1,779.62	2,774.03	3,554.10	6,739.90		
Less: 1. Interest	1,157.77	1,132.37	1,502.14	2,290.14	2,994.96	5,605.93		
2. Other Un-allocable Expenditure								
3. Un-allocable Income								
Total Profit Before Tax	210.67	273.22	277.48	483.88	559.13	1,133.96		
3. Capital Employed								
a. Speciality Chemicals Business	75,748.93	74,972.41	79,173.69	75,748.93	79,173.69	82,886.89		
b. Pharma Business	51,558.51	46,135.87	32,244.29	51,558.51	32,244.29	38,708.06		
Total	1,27,307.43	1,21,108.28	1,11,417.99	1,27,307.43	1,11,417.99	1,21,594.95		

Place : Hyderabad
Date : 12.11.2016

For VIVIMED LABS LIMITED
(SANTOSH VARALWAR)
MANAGING DIRECTOR



S.No	Particulars	STANDALONE		CONSOLIDATED	
		As at	As at	As at	As at
		30.09.2016 (Un-Audited)	31.03.2016 (Audited)	30.09.2016 (Un-Audited)	31.03.2016 (Audited)
(A)	EQUITY AND LIABILITIES				
1	Shareholders funds				
	(a) Share Capital				
	i) Equity Share Capital	1,620.38	1,620.38	1,620.38	1,620.38
	ii) Preference Share capital			6,394.56	6,394.56
	(b) Reserves and Surplus	36,198.67	35,343.76	53,494.95	50,500.31
	(c) Money Received against Share Warrants				
	Sub Total Shareholders Funds	37,819.05	36,964.14	61,509.89	58,515.25
2	Non-current liabilities				
	a) Long-term borrowings	20,445.63	19,303.22	24,317.87	25,726.94
	(b) Deferred tax liabilities (net)	3,253.67	3,253.67	1,238.68	1,069.94
	(c) Other long-term liabilities	37,372.50	32,103.98	32,459.72	28,956.50
	(d) Long-term provisions	334.96	338.18	362.34	357.29
	Sub-total - Non-current liabilities	61,406.75	54,999.05	58,378.62	56,110.66
3	Current liabilities				
	(a) Short-term borrowings	28,081.63	29,190.58	39,081.47	40,775.95
	(b) Trade payables	2,894.96	2,444.97	17,937.34	16,673.97
	(c) Other current liabilities	9,168.60	11,408.28	25,401.31	28,585.38
	(d) Short-term provisions	1,741.50	1,531.43	5,389.69	3,705.61
	Sub-total - Current liabilities	41,886.70	44,575.25	87,809.82	89,740.91
	TOTAL - EQUITY AND LIABILITIES	1,41,112.50	1,36,538.44	2,07,698.32	2,04,366.82
(B)	ASSETS				
1	Non-current assets				
	(a) Fixed assets				
	(i) Tangible Assets	37,180.08	37,623.54	70,690.55	71,490.93
	(ii) Intangible Assets	1,016.74	1,070.25	9,760.90	9,925.89
	(iii) Capital work in progress	4,328.71	4,082.88	9,396.39	9,416.91
	(b) Non Current Investment	23,004.55	23,004.55	272.92	268.92
	(c) Long Term Loans and advances				
	(d) Other Non Current Assets		-	0.29	4.39
	Sub-total - Non-current assets	65,530.08	65,781.23	90,121.05	91,107.05
2	Current Assets				
	(a) Inventories	27,636.82	26,817.08	50,611.69	49,079.70
	(b) Trade receivables	24,229.84	23,085.96	28,575.86	32,624.08
	(c) Cash and cash equivalents	533.24	717.56	2,303.52	3,095.80
	(d) Short-term loans and advances	22,589.37	19,543.46	34,883.86	27,287.67
	(e) Other current assets	593.14	593.14	1,202.34	1,172.53
	Sub-total - Current assets	75,582.41	70,757.21	1,17,577.27	1,13,259.78
	TOTAL - ASSETS	1,41,112.50	1,36,538.44	2,07,698.32	2,04,366.83






P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

To
The Board of Directors
VIVIMED LABS LIMITED
Hyderabad

Limited Review Report for Standalone Financials for the quarter ended 30th September, 2016

1. We have reviewed the accompanying statement of unaudited Standalone financial results of M/s. Vivimed Labs Limited for the quarter ended 30th September, 2016, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors in their meeting held on 12th November, 2016. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of interim financial information performed by the independent auditor of the entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure requirements) Regulations, 2015 and SEBI circular dated 05th July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S


P Murali Mohana Rao
Partner
M.No. 023412



Place: Hyderabad
Date: 12th November, 2016